trending Market Intelligence /marketintelligence/en/news-insights/trending/x53h6rjdirtzfc0cabgcrq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Oncology Venture nabs global rights to drug response prediction technology

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles

Energy

Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018


Oncology Venture nabs global rights to drug response prediction technology

Oncology Venture Sweden AB secured global exclusive development rights to Medical Prognosis Institute A/S' drug response prediction technology for a period of three years.

Oncology Venture will issue purchase warrants in exchange for the technology to develop new treatments. The warrants will be exercisable at 10 Swedish kronor for every share issued until Dec. 31, 2019.

Furthermore, Medical Prognosis will receive an ownership stake in Oncology Venture's special purpose vehicles instead of payments and earnings from the sale of the drugs developed by the technology.

As of Dec. 29, US$1 was equivalent to 9.12 Swedish kronor.